Gabrielle Gache

SAPPIENS (French/Swiss Biotech) is driving the clinical development of CXS003 for the treatment of Parkinson's disease, aiming at providing the 1st disease-modifying treatment.

Fractional C-level executive, Advisor in M&A, Partnering, Licensing and Business Development - M&A and Deal making, Capital-raising strategies, M&A Transaction, Due Diligence - Licensing-in /out and Deal structuring - Corporate / Business Strategy and Development

- Business Development - Strategy and Corporate Development - Geographic expansion Healthcare | Pharma, Rx, MD, OTC | Digital programs

Identified and drove the development of a portfolio of new ventures (immunotherapeutic products addressing acute and chronic immunological disorders resulting from infections and inflammation),, all supported by investment cases validated by experts in the field and presented to potential partners and investors. Mobilised cross-functional teams at local and corporate level, drove 'M&A integration' towards an independent company, supervised setting up of multiple SLAs guaranteeing business continuity,oversaw carve-out activities with new legal entity set-up and Swissmedic certification. Responsible for market driven licensing and access management.

Member of the Leadership team at OM Pharma Ltd ¦ Strategic partner of key leaders for each function along the entire chain of innovation. As part of the assets, contributed to the success of the sale of the company alongside to the CEO and enabled timely execution of the deal within 6 months only, including data-room set up and due diligence, management presentations, mobilisation of 20 executives. Managed the strategy finding process at OM Pharma, proposed a game-changing market driven growth strategy to Vifor Pharma Board of Directors, and got it successfully approved. Restructured and negotiated multiple strategic needle-moving out-licensing deals, strategic collaboration and in-licensing agreements, increasing company sales by MCHF 40 MCHF between strategy sign-off and sale. Build relevant business and investment cases articulating market-driven disease area strategies with clearly differentiated competitive advantage, by integrating comprehensively Drug Development, Regulatory, Market Access and Commercialization constraints Led evaluation of external business growth opportunities and assets.

Member of the Executive Committee Imagined and negotiated value creating deals satisfying both parties including new business models and deal structures, thus sustaining companies’ short-, mid- and long-term objectives. Inspired cross-functional teams, led more than 10 access and launch projects thus bringing meaningful innovation to Swiss Healthcare market, from Swissmedic registration to reimbursement and launch, in multiple specialty and orphan disease areas. Performance track record in rapid onset of deal execution. Led all in-licensing and commercial development activities, due diligence processes and negotiations. Cross-functional Team Leadership for Company Strategy and Brand Plans development, including epi-based forecasting. Led Business Intelligence, Market Research and Sales Force Effectiveness activities for a MCHF 100 business, 2 business units and multiple therapeutic areas.

Responsibilities included: - All in-licensing and commercial development activities - Partnermanagement - Launch Readiness - Cross-functional Leadership and Project Management - Leading Competitive insights and Market Research activities, Communications and Media Planning

In this global function, responsible for the flagship brand Ferinject (iron deficiency), in 3 therapeutic areas: IBD, Surgery and iron deficiency without anaemia. Organised Vifor's first international congress participation at the euroanaesthesia (ESA) congress in Italy.

executive program certificate

https://acad.ch/

http://www.acad.ch/